Dermatitis herpetiformis (DH), bullous pemphigoid (BP), and pemphigus vulgaris (PV) are autoimmune bullous skin conditions with eosinophilic and neutrophilic infiltrations. While cytokines are crucial for the affinity and activation of different leukocyte cells in the inflammation and blister formation, there are no studies concerning a role of IL-36. The goal of the study was to analyze whether interleukin 36 is involved in pathogenesis of DH, BP, and PV. And the second aim of the study was the estimation of correlation between Il-36 and IL-17 and titers of specific antibodies in these diseases. Expression of IL-36 and IL-17 was detected in serum in all DH, BP, and PV samples. Serum levels of IL-36 and IL-17α were statistically higher in DH, BP, and PV groups as compared to the control group. IL-36α levels were statistically higher in DH patients, as compared to patients with PV and BP. Our results showed that IL-36 may be helpful in the diagnostic and monitoring of the activity of the disease. IL 36 may play a relevant role of enrolling eosinophils and neutrophils in DH, BP, and PV and finally provoke tissue injury.
Background: The JAK/STAT signal pathway is a system of intracellular proteins used by many cytokines and growth factors to express genes responsible for the process of cell activation, proliferation and differentiation. There has been numerous inflammatory and autoimmune diseases identified where the JAK/STAT signaling is disrupted; however, there are only a few papers concerning autoimmune bullous diseases published. The aim of this study was to evaluate the expression of proteins: JAK3, STAT2, STAT4 and STAT6 in epithelium lesions in patients with pemphigus vulgaris (PV), bullous pemphigoid (BP), oral lichen planus (LP) and chronic ulcerative stomatitis (CUS), as well as in the control group. Methods: Immunohistochemistry and immunoblotting were used to evaluate expression of selected proteins. Results: We found significantly higher expression of selected JAK/STAT proteins in oral mucosa lesions in study groups in comparison to the control group, which indicates participation of JAK/STAT pathway in pathogenesis of these diseases. In BP and PV there were no increased STAT2 expression, whereas in CUS and LP no increased STAT4 expression occurred. Conclusions: The differences in expression of JAK/STAT proteins in selected disorders have been observed. These results create new potential therapeutic targets for the treatment.
Disorders of the oral mucosa are an area of interdisciplinary cooperation involving physicians from a diverse range of medical specialties. Diseases characterized by a similar mucosal abnormalities include lichen planus, pemphigus vulgaris, paraneoplastic pemphigus, mucous membrane pemphigoid, epidermolysis bullosa acquisita, linear IgA bullous dermatosis and chronic ulcerative stomatitis. streszCzenie Choroby błony śluzowej jamy ustnej stanowią obszar interdyscyplinarnej współpracy lekarzy wielu specjalności. Do jednostek chorobowych o podobnym obrazie klinicznym zmian występujących na błonach ślu-zowych należą: liszaj płaski jamy ustnej, pęcherzyca zwykła, pęcherzy-ca paraneoplastyczna, pemfigoid błon śluzowych, nabyte pęcherzowe oddzielanie się naskórka, linijna IgA dermatoza pęcherzowa oraz przewlekłe wrzodziejące zapalenie jamy ustnej.Key words: lichen planus, pemphigus vulgaris, paraneoplastic pemphigus, mucous membrane pemphigoid, epidermolysis bullosa acquisita, chronic ulcerative stomatitis. Słowa kluczowe: liszaj płaski, pęcherzyca zwykła, pęcherzyca paraneo plastyczna, pemfigoid błon śluzowych, nabyte pęcherzowe oddzielanie się naskórka, przewlekłe wrzodziejące zapalenie jamy ustnej.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.